FDA halts the use of GSK's Covid-19 drug completely as BA.2 subvariant blankets the country
It only took the Omicron BA.2 subvariant three business days to go from shutting down GlaxoSmithKline and Vir Biotechnology’s Covid-19 treatment sotrovimab in 22 states, as of last Friday, to the FDA completely shutting off use of the monoclonal antibody nationwide on Tuesday afternoon.
The decision was made as the CDC now estimates that the proportion of Covid-19 cases caused by BA.2 is above 50% nationwide.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.